The objective of this study is to assess the efficacy of Adalimumab in the treatment of MDD
Design
Randomized double blind and placebo-controlled clinical trial
Settings and conduct
The study will be conducted among adults with major depressive disorder attending Roozbeh Hospital
Participants/Inclusion and exclusion criteria
Inclusion criteria: presence of Major Depressive Disorder based on DSM-5 criteria; baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 19, CRP equals or more than 3 mg/lit.
Exclusion criteria: presence of psychosis, any other mental disorder; presence of hypothyroidism or cardiovascular problems; pregnancy or nursing women; history of tubercluosis; autoimmune disease; viral hepatitis; HIV; receiving ECT during the last two months; substance use; significant suicidal ideation
Intervention groups
The participants will be randomly allocated into two groups. Intervention group(25 persons) will receive Adalimumab (5mg/kg at the begenning) and sertraline ( up to 100 mg per day) for 6 weeks and control group ( 25 persons) will receive placebo at the beginning and sertraline ( up to 100 mg per day) for 6 weeks.
Main outcome variables
Severity of depression
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20090117001556N121
Registration date:2019-10-19, 1398/07/27
Registration timing:prospective
Last update:2019-10-19, 1398/07/27
Update count:0
Registration date
2019-10-19, 1398/07/27
Registrant information
Name
Shahin Akhondzadeh
Name of organization / entity
Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 5541 2222
Email address
s.akhond@sina.tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2019-11-21, 1398/08/30
Expected recruitment end date
2021-09-21, 1400/06/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Adalimumab as a adjuvant therapy in modrate to sever MDD in patients with CRP greater than or equal to 3mgr/lit : a double blind and randomized Trial
Public title
Adalimumab as a adjuvant therapy in modrate to sever MDD
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Presence of Major Depressive Disorder based on DSM-5 criteria
Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 19
CRP equals or more than 3mg/lit
Exclusion criteria:
Psychotic symptoms
Any other mental disorder
Hypothyroidism
Cardiovascular disease
Pregnant or nursing women
History of tuberculosis
Autoimmune disease
Viral hepatitis
Chronic or recurrent infections
Receiving ECT during the last two months
Significant suicidal ideation
Substance use
HIV
Age
From 18 years old to 60 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Care provider
Outcome assessor
Sample size
Target sample size:
50
Randomization (investigator's opinion)
Randomized
Randomization description
Random permuted block
Blinding (investigator's opinion)
Double blinded
Blinding description
The participants, clinicians and outcome raters will be blind regarding grouping
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Tehran University of Medical Sciences
Street address
Tehran University of Medical Sciences, Keshavarz Blv
City
Tehran
Province
Tehran
Postal code
1417653761
Approval date
2019-10-03, 1398/07/11
Ethics committee reference number
IR.TUMS.VCR.REC.1398.539
Health conditions studied
1
Description of health condition studied
Major Depressive Disorder
ICD-10 code
F32.1
ICD-10 code description
Major depressive disorder, single episode, moderate
Primary outcomes
1
Description
Severity of depression
Timepoint
Baseline and weeks 2,4 and 6
Method of measurement
By Hamiltion Depression Rating Scale 17-Item
Secondary outcomes
empty
Intervention groups
1
Description
Intervention group: Adalimumab(iv) 5 mg/kg at the beginning plus tablet sertralin up to100 mg/day for 6 weeks
Category
Treatment - Drugs
2
Description
Control group: placebo(iv) at the begenning plus tablet sertralin up to100 mg/day for 6 weeks
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Roozbeh Psychiaty Hospital
Full name of responsible person
Dr. Ahmad Ali Noorbala
Street address
South Kargar Street
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Email
s.akhond@sina.tums.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr Mohammad Ali Sahraian
Street address
Keshavarz Blvd
City
Tehran
Province
Tehran
Postal code
1417653761
Phone
+98 21 8898 7381
Email
Msahrai@tums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Roozbeh Hospital, South Kargar Street, Tehran
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Email
s.akhond@sina.tums.ac.ir
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Roozbeh Hospital, South Kargar Street, Tehran
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Fax
+98 21 5541 9113
Email
s.akhond@sina.tums.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Roozbeh Hospital, South Kargar Street, Tehran
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Fax
+98 21 5541 9113
Email
s.akhond@sina.tums.ac.ir
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Title and more details about the data/document
All data will be distributed through final report
When the data will become available and for how long
from 2021 to 2026
To whom data/document is available
academic researchers
Under which criteria data/document could be used
by email
From where data/document is obtainable
Prof Shahin Akhondzadeh
What processes are involved for a request to access data/document